Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Originally published in Science Express on 4 September 2008 Science 26 September 2008: Vol. 321. no. 5897, pp. 1801 - 1806
DOI: 10.1126/science.1164368
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones,1*Xiaosong Zhang,1*D. Williams Parsons,1,2*Jimmy Cheng-Ho Lin,1*Rebecca J. Leary,1*Philipp Angenendt,1*Parminder Mankoo,3Hannah Carter,3Hirohiko Kamiyama,4Antonio Jimeno,1Seung-Mo Hong,4Baojin Fu,4Ming-Tseh Lin,4Eric S. Calhoun,1Mihoko Kamiyama,4Kimberly Walter,4Tatiana Nikolskaya,5Yuri Nikolsky,6James Hartigan,7Douglas R. Smith,7Manuel Hidalgo,1Steven D. Leach,1,8Alison P. Klein,1,4Elizabeth M. Jaffee,1,4Michael Goggins,1,4Anirban Maitra,1,4Christine Iacobuzio-Donahue,1,4James R. Eshleman,1,4Scott E. Kern,1,4Ralph H. Hruban,1,4Rachel Karchin,3Nickolas Papadopoulos,1Giovanni Parmigiani,1,9Bert Vogelstein,1Victor E. Velculescu,1Kenneth W. Kinzler1
There are currently few therapeutic options for patients withpancreatic cancer, and new insights into the pathogenesis ofthis lethal disease are urgently needed. Toward this end, weperformed a comprehensive genetic analysis of 24 pancreaticcancers. We first determined the sequences of 23,219 transcripts,representing 20,661 protein-coding genes, in these samples.Then, we searched for homozygous deletions and amplificationsin the tumor DNA by using microarrays containing probes for106 single-nucleotide polymorphisms. We found that pancreaticcancers contain an average of 63 genetic alterations, the majorityof which are point mutations. These alterations defined a coreset of 12 cellular signaling pathways and processes that wereeach genetically altered in 67 to 100% of the tumors. Analysisof these tumors' transcriptomes with next-generation sequencing-by-synthesistechnologies provided independent evidence for the importanceof these pathways and processes. Our data indicate that geneticallyaltered core pathways and regulatory processes only become evidentonce the coding regions of the genome are analyzed in depth.Dysregulation of these core pathways and processes through mutationcan explain the major features of pancreatic tumorigenesis.
1 Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA. 2 Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX 77030, USA. 3 Department of Biomedical Engineering, Institute of Computational Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21218, USA. 4 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. 5 Vavilov Institute for General Genetics, Moscow B333, 117809, Russia. 6 GeneGo, Incorporated, St. Joseph, MI 49085, USA. 7 Agencourt Bioscience Corporation, Beverly, MA 01915, USA. 8 Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. 9 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: bertvog{at}gmail.com (B.V.); velculescu{at}jhmi.edu (V.E.V.); kinzlke{at}jhmi.edu (K.W.K.)
Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer.
A. Y. Shaw, M. C. Henderson, G. Flynn, B. Samulitis, H. Han, S. P. Stratton, H.-H. S. Chow, L. H. Hurley, and R. T. Dorr (2009)
J. Pharmacol. Exp. Ther.
331, 636-647
|Abstract »|Full Text »|PDF »
Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer.
T. Kubo, Y. Kuroda, H. Shimizu, A. Kokubu, N. Okada, F. Hosoda, Y. Arai, Y. Nakamura, H. Taniguchi, K. Yanagihara, et al. (2009)
Carcinogenesis
30, 1857-1864
|Abstract »|Full Text »|PDF »
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
M. L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stuckrath, J. Weiss, F. Fischer, et al. (2009)
PNAS
106, 18351-18356
|Abstract »|Full Text »|PDF »
A Modified Sleeping Beauty Transposon System That Can Be Used to Model a Wide Variety of Human Cancers in Mice.
A. J. Dupuy, L. M. Rogers, J. Kim, K. Nannapaneni, T. K. Starr, P. Liu, D. A. Largaespada, T. E. Scheetz, N. A. Jenkins, and N. G. Copeland (2009)
Cancer Res.
69, 8150-8156
|Abstract »|Full Text »|PDF »
Screening for familial pancreatic cancer: is doing something better than doing nothing?.
Microarray analysis of cytoplasmic versus whole cell RNA reveals a considerable number of missed and false positive mRNAs.
H. W. Trask, R. Cowper-Sal-lari, M. A. Sartor, J. Gui, C. V. Heath, J. Renuka, A.-J. Higgins, P. Andrews, M. Korc, J. H. Moore, et al. (2009)
RNA
15, 1917-1928
|Abstract »|Full Text »|PDF »
MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E-Binding Protein 1-Mediated Inhibition of Autophagy.
B. S. Balakumaran, A. Porrello, D. S. Hsu, W. Glover, A. Foye, J. Y. Leung, B. A. Sullivan, W. C. Hahn, M. Loda, and P. G. Febbo (2009)
Cancer Res.
69, 7803-7810
|Abstract »|Full Text »|PDF »
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
M. J. Duffy, C. Sturgeon, R. Lamerz, C. Haglund, V. L. Holubec, R. Klapdor, A. Nicolini, O. Topolcan, and V. Heinemann (2009)
Ann. Onc.
|Abstract »|Full Text »|PDF »
Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia.
K. Walter, S.-M. Hong, S. Nyhan, M. Canto, N. Fedarko, A. Klein, M. Griffith, N. Omura, S. Medghalchi, F. Kuhajda, et al. (2009)
Cancer Epidemiol. Biomarkers Prev.
18, 2380-2385
|Abstract »|Full Text »|PDF »
Saturation Density of Skin Fibroblasts as a Quantitative Screen for Human Cancer Susceptibility.
Multiplex padlock targeted sequencing reveals human hypermutable CpG variations.
J. B. Li, Y. Gao, J. Aach, K. Zhang, G. V. Kryukov, B. Xie, A. Ahlford, J.-K. Yoon, A. M. Rosenbaum, A. W. Zaranek, et al. (2009)
Genome Res.
19, 1606-1615
|Abstract »|Full Text »|PDF »
Identification of rare cancer driver mutations by network reconstruction.
Fluorescence In Situ Hybridization to Visualize Genetic Abnormalities in Interphase Cells of Acinar Cell Carcinoma, Ductal Adenocarcinoma, and Islet Cell Carcinoma of the Pancreas.
G. W. Dewald, T. C. Smyrk, E. C. Thorland, R. R. McWilliams, D. L. Van Dyke, J. G. Keefe, K. J. Belongie, S. A. Smoley, D. L. Knutson, S. R. Fink, et al. (2009)
Mayo Clin. Proc.
84, 801-810
|Abstract »|Full Text »|PDF »
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations.
H. Carter, S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and R. Karchin (2009)
Cancer Res.
69, 6660-6667
|Abstract »|Full Text »|PDF »
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group.
E. Poplin, Y. Feng, J. Berlin, M. L. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'Dwyer, D. Haller, P. Catalano, et al. (2009)
J. Clin. Oncol.
27, 3778-3785
|Abstract »|Full Text »|PDF »
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia.
I. Radtke, C. G. Mullighan, M. Ishii, X. Su, J. Cheng, J. Ma, R. Ganti, Z. Cai, S. Goorha, S. B. Pounds, et al. (2009)
PNAS
106, 12944-12949
|Abstract »|Full Text »|PDF »
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.
S. Ocak, M. L. Sos, R. K. Thomas, and P. P. Massion (2009)
Eur. Respir. J.
34, 489-506
|Abstract »|Full Text »|PDF »
Organotypic Culture Model of Pancreatic Cancer Demonstrates that Stromal Cells Modulate E-Cadherin, {beta}-Catenin, and Ezrin Expression in Tumor Cells.
F. E.M. Froeling, T. A. Mirza, R. M. Feakins, A. Seedhar, G. Elia, I. R. Hart, and H. M. Kocher (2009)
Am. J. Pathol.
175, 636-648
|Abstract »|Full Text »|PDF »
MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins.
D. Lam, D. Dickens, E. B. Reid, S. H. Y. Loh, N. Moisoi, and L. M. Martins (2009)
PNAS
106, 11978-11983
|Abstract »|Full Text »|PDF »
A Genome-wide Short Hairpin RNA Screening of Jurkat T-cells for Human Proteins Contributing to Productive HIV-1 Replication.
M. L. Yeung, L. Houzet, V. S. R. K. Yedavalli, and K.-T. Jeang (2009)
J. Biol. Chem.
284, 19463-19473
|Abstract »|Full Text »|PDF »
Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells.
A. Corthay, K. U. Lundin, K. B. Lorvik, P. O. Hofgaard, and B. Bogen (2009)
Cancer Res.
69, 5901-5907
|Abstract »|Full Text »|PDF »
Sample Type Bias in the Analysis of Cancer Genomes.
D. A. Solomon, J.-S. Kim, H. W. Ressom, Z. Sibenaller, T. Ryken, W. Jean, D. Bigner, H. Yan, and T. Waldman (2009)
Cancer Res.
69, 5630-5633
|Abstract »|Full Text »|PDF »
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer.
A. Blackford, O. K. Serrano, C. L. Wolfgang, G. Parmigiani, S. Jones, X. Zhang, D. W. Parsons, J. C.-H. Lin, R. J. Leary, J. R. Eshleman, et al. (2009)
Clin. Cancer Res.
15, 4674-4679
|Abstract »|Full Text »|PDF »
Genetic Inactivation of ADAMTS15 Metalloprotease in Human Colorectal Cancer.
C. G. Viloria, A. J. Obaya, A. Moncada-Pazos, M. Llamazares, A. Astudillo, G. Capella, S. Cal, and C. Lopez-Otin (2009)
Cancer Res.
69, 4926-4934
|Abstract »|Full Text »|PDF »
Challenges in the Search for Drugs to Treat Central Nervous System Disorders.
Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer.
A. Blackford, G. Parmigiani, T. W. Kensler, C. Wolfgang, S. Jones, X. Zhang, D. W. Parsons, J. C.-H. Lin, R. J. Leary, J. R. Eshleman, et al. (2009)
Cancer Res.
69, 3681-3688
|Abstract »|Full Text »|PDF »
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene.
S. Jones, R. H. Hruban, M. Kamiyama, M. Borges, X. Zhang, D. W. Parsons, J. C.-H. Lin, E. Palmisano, K. Brune, E. M. Jaffee, et al. (2009)
Science
324, 217
|Abstract »|Full Text »|PDF »
Absence of Deleterious Palladin Mutations in Patients with Familial Pancreatic Cancer.
A. P. Klein, M. Borges, M. Griffith, K. Brune, S.-M. Hong, N. Omura, R. H. Hruban, and M. Goggins (2009)
Cancer Epidemiol. Biomarkers Prev.
18, 1328-1330
|Abstract »|Full Text »|PDF »
Multiple Genes Exhibit Phenobarbital-Induced Constitutive Active/Androstane Receptor-Mediated DNA Methylation Changes during Liver Tumorigenesis and in Liver Tumors.
Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer.
M. E. Mullendore, J.-B. Koorstra, Y.-M. Li, G. J. Offerhaus, X. Fan, C. M. Henderson, W. Matsui, C. G. Eberhart, A. Maitra, and G. Feldmann (2009)
Clin. Cancer Res.
15, 2291-2301
|Abstract »|Full Text »|PDF »
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis.
H. Tian, C. A. Callahan, K. J. DuPree, W. C. Darbonne, C. P. Ahn, S. J. Scales, and F. J. de Sauvage (2009)
PNAS
106, 4254-4259
|Abstract »|Full Text »|PDF »
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.
S. Sur, R. Pagliarini, F. Bunz, C. Rago, L. A. Diaz Jr., K. W. Kinzler, B. Vogelstein, and N. Papadopoulos (2009)
PNAS
106, 3964-3969
|Abstract »|Full Text »|PDF »
Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination.
T. H. Schreiber, V. V. Deyev, J. D. Rosenblatt, and E. R. Podack (2009)
Cancer Res.
69, 2026-2033
|Abstract »|Full Text »|PDF »
Is Anticancer Drug Development Heading in the Right Direction?.
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.
O. Nolan-Stevaux, J. Lau, M. L. Truitt, G. C. Chu, M. Hebrok, M. E. Fernandez-Zapico, and D. Hanahan (2009)
Genes & Dev.
23, 24-36
|Abstract »|Full Text »|PDF »
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
K. Ichimura, D. M. Pearson, S. Kocialkowski, L. M. Backlund, R. Chan, D. T.W. Jones, and V. P. Collins (2009)
Neuro-oncol
11, 341-347
|Abstract »|Full Text »|PDF »
MODBASE, a database of annotated comparative protein structure models and associated resources.
U. Pieper, N. Eswar, B. M. Webb, D. Eramian, L. Kelly, D. T. Barkan, H. Carter, P. Mankoo, R. Karchin, M. A. Marti-Renom, et al. (2009)
Nucleic Acids Res.
37, D347-D354
|Abstract »|Full Text »|PDF »
Enzymes and Cancer: A Look Toward the Past as We Move Forward.
K. I. Block (2008)
Integr Cancer Ther
7, 223-225
|PDF »
An Integrated Genomic Analysis of Human Glioblastoma Multiforme.
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al. (2008)
Science
321, 1807-1812
|Abstract »|Full Text »|PDF »